Unlock stock picks and a broker-level newsfeed that powers Wall Street.
KOSDAQ - Delayed Quote KRW

TELCON RF PHARMACEUTICAL. Inc. (200230.KQ)

Compare
3,030.00
-10.00
(-0.33%)
At close: April 4 at 3:30:20 PM GMT+9
Loading Chart for 200230.KQ
  • Previous Close 3,040.00
  • Open 2,970.00
  • Bid 3,035.00 x --
  • Ask 3,100.00 x --
  • Day's Range 2,970.00 - 3,130.00
  • 52 Week Range 2,970.00 - 9,300.00
  • Volume 18,606
  • Avg. Volume 21,518
  • Market Cap (intraday) 36.436B
  • Beta (5Y Monthly) 0.65
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date May 14, 2025 - May 19, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

TELCON RF PHARMACEUTICAL. Inc. primarily engages in the development, production, and sale of RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies; and pharmaceuticals. The company was formerly known as Telcon Co., Ltd. TELCON RF PHARMACEUTICAL. Inc. was founded in 1999 and is headquartered in Yongin-si, South Korea.

www.telcon.co.kr

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 200230.KQ

View More

Performance Overview: 200230.KQ

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

200230.KQ
48.38%
KOSPI Composite Index (^KS11)
2.75%

1-Year Return

200230.KQ
60.75%
KOSPI Composite Index (^KS11)
10.09%

3-Year Return

200230.KQ
87.43%
KOSPI Composite Index (^KS11)
10.61%

5-Year Return

200230.KQ
94.84%
KOSPI Composite Index (^KS11)
42.89%

Compare To: 200230.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 200230.KQ

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    36.44B

  • Enterprise Value

    82.09B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.95

  • Price/Book (mrq)

    0.44

  • Enterprise Value/Revenue

    2.17

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -69.51%

  • Return on Assets (ttm)

    -0.03%

  • Return on Equity (ttm)

    -28.18%

  • Revenue (ttm)

    37.87B

  • Net Income Avi to Common (ttm)

    -26.32B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.04B

  • Total Debt/Equity (mrq)

    66.99%

  • Levered Free Cash Flow (ttm)

    10.35B

Research Analysis: 200230.KQ

View More

Company Insights: 200230.KQ

Research Reports: 200230.KQ

View More

People Also Watch